Keyword "RETINAL ISCHEMIA-REPERFUSION" found in the following publications:

PHARMACOLOGICAL PRECONDITIONING BY RECOMBINANT ERYTHROPOIETIN AS THE POSSIBILITY OF INCREASING THE STABILITY OF TISSUE OF THE RETINA TO REPERFUSION ISCHEMIA IN EXPERIMENT
Ischemic injury was formed in laboratory rats by applying mechanical pressure (110 mm Hg) to the anterior eye chamber for ...
Abstract | Full text (PDF)
CORRECTION OF ISCHEMIC AND REPERFUSION DAMAGE IN THE RETINA BY USING IMIDAZOLINE RECEPTORS AGONISTS OF TYPES I, II IN RATS
Background: The authors note that special literature does not make mention of drugs for targeted, specific correction of retinal ...
Abstract | Full text (PDF)
CORRECTION OF RETINAL ISCHEMIC INJURIES BY USING NON-SELECTIVE IMIDAZOLINE RECEPTOR AGONISTS IN THE EXPERIMENT
Introduction: Retinoprotective effects of non-selective imidazoline receptor agonists: potassium salt of С7070; sodium salt of С7070; С7070 processed with CO₂ – ...
Abstract | Full text (PDF)

Research Results in Biomedicine is included in the scientific database of the RINTs (license agreement No. 765-12/2014 dated 08.12.2014).

The journal is included in the list of peer-reviewed scientific publications recommended by the Higher Attestation Commission

The journal is indexed by the following scientific databases and platforms

Research Results in Biomedicine (ISSN 2658-6533)

The journal materials and website are licensed under Creative Commons «Attribution» 4.0 International.

The Founder: Federal State Autonomous Educational Institution of Higher Education "Belgorod National Research University"The Founder’s address: 85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

The Publisher: Federal State Autonomous Educational Institution of HigherEducation "Belgorod National Research University" The Founder’s address:85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

Editors Office: chief editor Mikhail I. Churnosov, e-mail: RR_MedPharm@bsuedu.ru, phone: +7 (4722) 30-14-03.

Regulations on the Journal

Certificate

Have questions?
You can write to us:

✉ Executive Secretary

✉ Site administration

✉ Content manager